Skip to main content
Erschienen in: Annals of Surgical Oncology 12/2010

01.12.2010 | Thoracic Oncology

Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer

Erschienen in: Annals of Surgical Oncology | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Studies have shown that along with primary tumor response, lymph node status after RTx/CTx is one of the most important prognostic factors for advanced esophageal carcinoma. The goal of our study was to investigate the influence of neoadjuvant radiochemotherapy (RTx/CTx) on lymph nodes (LN).

Materials and Methods

From 1997 until 2006, 297 patients underwent surgery for advanced esophageal carcinoma. Of these, 192 received preoperative chemoradiation (5-FU, cisplatin, 36 Gy). The following matched subgroups were chosen: Group I, 20 with surgery alone: 10 adenocarcinoma (AC), 10 squamous cell carcinoma (SCC); Group II, 20 with minor response (10 AC, 10 SCC); Group III, 20 with major response (10 AC, 10 SCC). Tumor response was graded as “minor” or “major” according to the Cologne Regression Scale, the LN size determined by the largest measured diameter.

Results

A total of 1967 LNs from 60 patients were examined. Of these, 161 LNs showed metastasis. The median number of LNs examined per patient was not significantly higher in group I compared with the group with pretreatment (32 vs 31). Group I and group II showed LN metastasis (LNM) in 65% of cases, and group III in only 20% (p = 0.011). LNMs after pretreatment had significantly smaller median diameters (5.0 mm) than those without (7.0 mm) (p < 0.02). Nonmetastatic LN size did not vary between the three groups. LN size with and without metastasis did not differ between AC and SCC or between major and minor responders.

Conclusion

With good response to neoadjuvant radiochemotherapy, the size and the number of metastatic LNs is significantly reduced regardless of histologic cancer type.
Literatur
1.
Zurück zum Zitat Stahl M, Walz M, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.CrossRefPubMed Stahl M, Walz M, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851–6.CrossRefPubMed
2.
Zurück zum Zitat Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.CrossRefPubMed Tepper J, Krasna M, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086–92.CrossRefPubMed
3.
Zurück zum Zitat Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction—the impact of clinical heterogeneity. Am J Clin Oncol. 2007;30:172–80.CrossRefPubMed Adelstein DJ, Rice TW, Rybicki LA, Saxton JP, Videtic GM, Murthy SC, et al. A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction—the impact of clinical heterogeneity. Am J Clin Oncol. 2007;30:172–80.CrossRefPubMed
4.
Zurück zum Zitat Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231–8.CrossRefPubMed Bollschweiler E, Metzger R, Drebber U, Baldus S, Vallböhmer D, Kocher M, et al. Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol. 2009;20:231–8.CrossRefPubMed
5.
Zurück zum Zitat Schneider P, Baldus S, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.CrossRefPubMed Schneider P, Baldus S, Metzger R, Kocher M, Bongartz R, Bollschweiler E, et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242:684–92.CrossRefPubMed
6.
Zurück zum Zitat Mariette C, Piessen G, Briez N, Triboulet J. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRefPubMed Mariette C, Piessen G, Briez N, Triboulet J. The number of metastatic lymph nodes and the ratio between metastatic and examined lymph nodes are independent prognostic factors in esophageal cancer regardless of neoadjuvant chemoradiation or lymphadenectomy extent. Ann Surg. 2008;247:365–71.CrossRefPubMed
7.
Zurück zum Zitat Prenzel K, Konig A, Schneider P, Schnickmann C, Baldus SE, Schroder W, et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol. 2007;14:954–9.CrossRefPubMed Prenzel K, Konig A, Schneider P, Schnickmann C, Baldus SE, Schroder W, et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol. 2007;14:954–9.CrossRefPubMed
8.
Zurück zum Zitat Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med. 1996;335:462–7.CrossRefPubMed Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TPJ. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. New Engl J Med. 1996;335:462–7.CrossRefPubMed
9.
Zurück zum Zitat Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J Surg. 2006;30:2182–90; discussion 2191–2.CrossRefPubMed Rouvelas I, Zeng W, Lindblad M, Viklund P, Ye W, Lagergren J. Survival after neoadjuvant therapy compared with surgery alone for resectable esophageal cancer in a population-based study. World J Surg. 2006;30:2182–90; discussion 2191–2.CrossRefPubMed
10.
Zurück zum Zitat Read T, Andujar J, Caushaj P, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004;47:825–31.CrossRefPubMed Read T, Andujar J, Caushaj P, Johnston DR, Dietz DW, Myerson RJ, et al. Neoadjuvant therapy for rectal cancer: histologic response of the primary tumor predicts nodal status. Dis Colon Rectum. 2004;47:825–31.CrossRefPubMed
11.
Zurück zum Zitat Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009;10:785–93.CrossRefPubMed Stupp R, Mayer M, Kann R, Weder W, Zouhair A, Betticher DC, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in selected patients with stage IIIB non-small-cell lung cancer: a multicentre phase II trial. Lancet Oncol. 2009;10:785–93.CrossRefPubMed
12.
Zurück zum Zitat Schröder W, Baldus S, Monig S, Beckurts T, Dienes H, Hölscher A. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg. 2002;26:584–7.CrossRefPubMed Schröder W, Baldus S, Monig S, Beckurts T, Dienes H, Hölscher A. Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy: histomorphologic analysis. World J Surg. 2002;26:584–7.CrossRefPubMed
13.
Zurück zum Zitat Sobin L, Wittekind C. UICC (2002) TNM Classification of Malignant Tumors. 6th ed. New York: Wiley & Sons, 2002. Sobin L, Wittekind C. UICC (2002) TNM Classification of Malignant Tumors. 6th ed. New York: Wiley & Sons, 2002.
14.
Zurück zum Zitat Hölscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P. How safe is high intrathoracic esophagogastrostomy? Chirurg. 2003;74:726–33.CrossRefPubMed Hölscher A, Schroder W, Bollschweiler E, Beckurts K, Schneider P. How safe is high intrathoracic esophagogastrostomy? Chirurg. 2003;74:726–33.CrossRefPubMed
15.
Zurück zum Zitat Baldus S, Monig S, Schroder W, Metzger R, Lang S, Zirbes TK, et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe. 2004;25:421–7.CrossRefPubMed Baldus S, Monig S, Schroder W, Metzger R, Lang S, Zirbes TK, et al. Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation. Pathologe. 2004;25:421–7.CrossRefPubMed
16.
Zurück zum Zitat Wichmann M, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg. 2002;137:206–10.CrossRefPubMed Wichmann M, Muller C, Meyer G, Strauss T, Hornung HM, Lau-Werner U, et al. Effect of preoperative radiochemotherapy on lymph node retrieval after resection of rectal cancer. Arch Surg. 2002;137:206–10.CrossRefPubMed
17.
Zurück zum Zitat Maschuw K, Kress R, Ramaswamy A, Braun I, Langer P, Gerdes B. Short-term preoperative radiotherapy in rectal cancer patients leads to a reduction of the detectable number of lymph nodes in resection specimens. Langenbecks Arch Surg. 2006;391:364–8.CrossRefPubMed Maschuw K, Kress R, Ramaswamy A, Braun I, Langer P, Gerdes B. Short-term preoperative radiotherapy in rectal cancer patients leads to a reduction of the detectable number of lymph nodes in resection specimens. Langenbecks Arch Surg. 2006;391:364–8.CrossRefPubMed
18.
Zurück zum Zitat Taflampas P, Christodoulakis M, Gourtsoyianni S, Leventi K, Melissas J, Tsiftsis D. The effect of preoperative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer. Dis Colon Rectum. 2009;52:1470–4.PubMed Taflampas P, Christodoulakis M, Gourtsoyianni S, Leventi K, Melissas J, Tsiftsis D. The effect of preoperative chemoradiotherapy on lymph node harvest after total mesorectal excision for rectal cancer. Dis Colon Rectum. 2009;52:1470–4.PubMed
19.
Zurück zum Zitat Perez R, Pereira D, Proscurshim I, Gama-Rodrigues J, Rawet V, São Julião GP, Kiss D, Cecconello I, Habr-Gama A. et al. Lymph node size in rectal cancer following neoadjuvant chemoradiation—can we rely on radiologic nodal staging after chemoradiation? Dis Colon Rectum. 2009;52:1278–84.PubMed Perez R, Pereira D, Proscurshim I, Gama-Rodrigues J, Rawet V, São Julião GP, Kiss D, Cecconello I, Habr-Gama A. et al. Lymph node size in rectal cancer following neoadjuvant chemoradiation—can we rely on radiologic nodal staging after chemoradiation? Dis Colon Rectum. 2009;52:1278–84.PubMed
20.
Zurück zum Zitat Twine C, Lewis W, Morgan M, Chan D, Clark GW, Havard T, et al. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology. 2009;55:46–52.CrossRefPubMed Twine C, Lewis W, Morgan M, Chan D, Clark GW, Havard T, et al. The assessment of prognosis of surgically resected oesophageal cancer is dependent on the number of lymph nodes examined pathologically. Histopathology. 2009;55:46–52.CrossRefPubMed
21.
Zurück zum Zitat Greenstein A, Litle V, Swanson S, Divino C, Packer S, Wisnivesky J. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.CrossRefPubMed Greenstein A, Litle V, Swanson S, Divino C, Packer S, Wisnivesky J. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239–46.CrossRefPubMed
22.
Zurück zum Zitat Wilson M, Rosato E, Chojnacki K, Chervoneva I, Kairys JC, Cohn HE, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146:11–5.CrossRefPubMed Wilson M, Rosato E, Chojnacki K, Chervoneva I, Kairys JC, Cohn HE, et al. Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res. 2008;146:11–5.CrossRefPubMed
23.
Zurück zum Zitat Peyre C, Hagen J, De MS, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRefPubMed Peyre C, Hagen J, De MS, Altorki NK, Ancona E, Griffin SM, et al. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549–56.CrossRefPubMed
24.
Zurück zum Zitat Altorki N, Zhou X, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRefPubMed Altorki N, Zhou X, Stiles B, Port JL, Paul S, Lee PC, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221–6.CrossRefPubMed
25.
Zurück zum Zitat Barbour A, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894–902.CrossRefPubMed Barbour A, Jones M, Gonen M, Gotley DC, Thomas J, Thomson DB, et al. Refining esophageal cancer staging after neoadjuvant therapy: importance of treatment response. Ann Surg Oncol. 2008;15:2894–902.CrossRefPubMed
26.
Zurück zum Zitat Jamieson G, Thompson S. Detection of lymph node metastases in oesophageal cancer. Br J Surg. 2009;96:21–5.CrossRefPubMed Jamieson G, Thompson S. Detection of lymph node metastases in oesophageal cancer. Br J Surg. 2009;96:21–5.CrossRefPubMed
27.
Zurück zum Zitat Adelstein D, Rice T, Becker M, Larto MA, Kirby TJ, Koka A, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011–20.CrossRefPubMed Adelstein D, Rice T, Becker M, Larto MA, Kirby TJ, Koka A, et al. Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma. Cancer. 1997;80:1011–20.CrossRefPubMed
28.
Zurück zum Zitat Schneider P, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902–8.CrossRefPubMed Schneider P, Metzger R, Schaefer H, Baumgarten F, Vallbohmer D, Brabender J, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902–8.CrossRefPubMed
29.
Zurück zum Zitat Leers J, Ayazi S, Hagen J, Terterov S, Klipfel N, Oezcelik A, et al. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg. 2009;208:553–6.CrossRefPubMed Leers J, Ayazi S, Hagen J, Terterov S, Klipfel N, Oezcelik A, et al. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg. 2009;208:553–6.CrossRefPubMed
30.
Zurück zum Zitat Metzger R, Drebber U, Baldus SE, Monig SP, Holscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann Surg Oncol. 2009;16:447–53.CrossRefPubMed Metzger R, Drebber U, Baldus SE, Monig SP, Holscher AH, Bollschweiler E: Extracapsular lymph node involvement differs between squamous cell and adenocarcinoma of the esophagus. Ann Surg Oncol. 2009;16:447–53.CrossRefPubMed
Metadaten
Titel
Influence of Neoadjuvant Chemoradiation on the Number and Size of Analyzed Lymph Nodes in Esophageal Cancer
Publikationsdatum
01.12.2010
Erschienen in
Annals of Surgical Oncology / Ausgabe 12/2010
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1196-8

Weitere Artikel der Ausgabe 12/2010

Annals of Surgical Oncology 12/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.